- 全部删除
- 您的购物车当前为空
Garenoxacin (BMS284756) 是一种新型的口服 des-fluoro(6) 喹诺酮,有抗菌活性,可抑制呼吸道病原体。
Garenoxacin (BMS284756) 是一种新型的口服 des-fluoro(6) 喹诺酮,有抗菌活性,可抑制呼吸道病原体。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | 待估 | 35日内发货 | |
10 mg | 待估 | 35日内发货 | |
25 mg | 待估 | 35日内发货 |
Garenoxacin 相关产品
产品描述 | Garenoxacin (BMS284756) is a novel oral des-fluoro(6) quinolone for the treatment of Gram-positive and Gram-negative bacterial infections. |
靶点活性 | TOPO IV:1.5-2.5 μg/mL, DNA gyrase:1.25 μg/mL |
体内活性 | 平均最大血浆浓度(Cmax)为3.00 ± 1.12 μg/mL,达到最大血浆浓度时间(Tmax)为3.0 ± 2.0小时,24小时内曲线下面积(AUC0-24)为40.7 ± 16.7 μg·h/mL。由于GRNX给药后24小时血浆浓度仍然较高,其半衰期(T1/2)无法计算。Cmax与GRNX每千克体重剂量强烈相关(r = 0.85, P = 0.03)。临床上,GRNX给药后3天内热症状消失,C反应蛋白水平在给药后14天回归正常。一位患者经历了血清转氨酶水平暂时性增加[1]。 |
动物实验 | Six male patients with infections who were undergoing MH received 200 mg GRNX once daily. Blood samples were taken before and at 1, 2, 4, 6, 12, and 24 hours after GRNX administration. Plasma GRNX concentrations were measured using high-performance liquid chromatography[1]. |
别名 | 加雷沙星, BMS284756 |
分子量 | 426.41 |
分子式 | C23H20F2N2O4 |
CAS No. | 194804-75-6 |
密度 | 1.421g/cm3 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||
溶解度信息 | DMSO: 2 mg/mL (4.69 mM), Sonication is recommended. | ||||||||||
溶液配制表 | |||||||||||
DMSO
|
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容